Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis

L-ornithine L-aspartate (LOLA) is administered as a therapeutic and/or preventive strategy against hepatic encephalopathy either intravenously or orally in patients with liver cirrhosis. Here, we analyzed how LOLA influences the microbiome and metabolome of patients with liver cirrhosis. We retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvath, Angela, Traub, Julia, Aliwa, Benard, Bourgeois, Benjamin, Madl, Tobias, Stadlbauer, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875633/
https://www.ncbi.nlm.nih.gov/pubmed/35215398
http://dx.doi.org/10.3390/nu14040748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875633/
https://www.ncbi.nlm.nih.gov/pubmed/35215398
http://dx.doi.org/10.3390/nu14040748

Ejemplares similares